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Introduction: A growing evidence suggests that immune dysregulation and thrombotic phenomena are key features
in the pathophysiology of COVID-19. Apart from antivirals and respiratory support, anticoagulants, corticoids and
immunomodulators are increasingly being prescribed, especially for more severe cases. We describe the clinical
outcome of a large cohort of patients preferentially treated with glucocorticoids and interleukin inhibitors.
Methods: Single center and retrospective case series. Adult patients admitted with COVID-19 related respiratory
insufficiency were included. Patients who died within 2 days after admission and those testing positive but
asymptomatic were excluded. We defined two study periods: from March 3rd to March 31 st, 2020 (beginning of
epidemic until peak of incidence) and April 1 st to May 7 th, 2020 (second half of epidemic). The majority of
patients received respiratory support, combinations of antimicrobials, anticoagulants, corticoids and interleukin
inhibitors. Antivirals were preferentially given in the first period. The clinical outcome (death and ventilator
dependency) of both periods was compared.
Results: From March 3 rd to May 7 th, 685 patients were included for analysis (58.4% males, mean age 68.9 years).
Patients in the first period (n ¼ 408) were younger (66.6 vs 71.1 years, p ¼ 0.003), presented lower mean P a O 2/
F i O2 ratio at admission (256.5 vs 270.4 mm Hg,p ¼ 0.0563), higher ferritin (1520 vs 1221 ng/ml, p ¼ 0.01),
higher IL-6 (679 vs 194 pg/ml, p < 0.0001) and similar D-dimer levels (3.59 vs 3.39 μg/mL, p ¼ 0.65) comparedfectious Diseases, Chief Department, Hospital Universitario de Burgos, Calle Islas Baleares S/N, 09006, Burgos,
, lbuzonm@saludcastillayleon.es (B.-M. Luis).
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B.-M. Luis et al. Journal of Translational Autoimmunity 4 (2021) 100086to the second period (n ¼ 277). Lopinavir/ritonavir and interferon were preferentially given in the first period
(23.8% and 32% vs 1.8% and 11.9%, p < 0.0001). Use of corticoids (88.2% vs 87.4%, p ¼ 0,74) and tocilizumab
(26.29 vs 20.22% p ¼ 0.06) were similarly administered in both periods. Patients in the second period needed less
mechanical ventilation (4.9% vs 16.9%, p < 0.0001), fewer ICU admission (6.1% vs 20.1%,p < 0.0001) and
showed similar mortality (17.7% vs 15.4%, p ¼ 0.43). Infectious and thrombotic complications were comparable
in both periods (both around 8%, with no statistical difference). Patients treated with tocilizumab (n ¼ 163) had
lower mortality rate compared to those untreated under the same indication (7.9% vs 24.2%, p < 0.0001).
Conclusions: In this large retrospective COVID-19 in-hospital cohort, lopinavir/ritonavir and interferon showed no
significant impact on survival. Extensive use of corticosteroids and tocilizumab resulted in good overall outcome
and showed acceptable complication rates.1. Introduction
COVID-19 pandemic is a worldwide concern affecting all countries
with different impact depending on the timing and aggressiveness of
implementation of public health measures [1,2]. Overall mortality rate
for moderate and severe cases exceed 15%, with some series reporting
over 25% [3–7]. Among those admitted to intensive care units (ICU) and
requiring mechanical ventilation, mortality can reach 50–70% [3,4,6,7].
A growing evidence suggests that immune dysregulation and
thrombotic phenomena are key features in the pathophysiology of
moderate and severe SARS-CoV-2 infection [4,8–11]. A certain state of
systemic hyperinflammation has been observed in many patients that
present rapid respiratory impairment and ventilator dependency [9,
11–13]. A percentage of these may also develop a characteristic massive
cytokine release with markedly increased immune inflammatory markers
[4,8,11]. In this context, a rationale for immunomodulatory therapy has
been proposed [8,10,11,14].
In fact, the use of corticoids and other immunomodulators in COVID-
19 has been controversial [14–18]. Initially most guidelines strongly
recommended against the use of glucocorticoids and other immuno-
modulatory agents outside clinical trials, alluding a theoretical prolonged
viral shedding and other complications [19–21]. However, in the last
months, substantial evidence favoring the administration of corticoids
[7,22–25] and interleukin inhibitors [26–31] has been published.
According to our particular epidemic scenario, we readily observed
that patients under corticoid therapy and those treated with interleukin
inhibitors seemed to fare better than those under regular antiviral and
antibiotic combination schemes. Additionally, we prescribed prophy-
lactic anticoagulation [32] as part of the treatment protocol early in the
course of the epidemic. We hypothesized that therapy based on the
combination of anti-inflammatory (mainly corticoid therapy) and anti-
coagulation would result in fewer ventilation dependency and ICU
admission, and lower complication and mortality rates.
Therefore, we reviewed the clinical course and outcome of a large
cohort of COVID-19 patients admitted to our tertiary center. These pa-
tients were preferentially treated with respiratory support and combi-
nations of drugs according to actuarial evidence and international
recommendations [19–32]. Yet, the great majority received methyl-
prednisolone and enoxaparin. Additionally, 163 patients were treated
with IL-6 inhibitor tocilizumab. We compared the clinical outcome of
patients before and after the peak incidence of the epidemic curve. An-
tivirals were used only in the first half of the epidemic. In this case series
review we aimed to provide evidence on the effectiveness and safety of
immunomodulatory therapy regarding the need for mechanical ventila-
tion, requirement of ICU stay, and overall mortality.
2. Patients and methods
2.1. Study design and inclusion criteria
We conducted a retrospective case series at the University Hospital of
Burgos, Spain, betweenMarch 3 and May 7, 2020. Our center is a tertiary
hospital with 700 beds (26 ICU beds) for a catchment area of 350,0002
people. The study was approved by the local Ethics Committee (CEIm
reference number: 2315) and informed consent was obtained from all
participants.
Patients were included if they were 18 years or older and were
admitted presenting COVID-19 related respiratory insufficiency upon
clinical and blood gas parameters. Patients who died within 48 h of
admission and those testing positive but asymptomatic were excluded.
Confirmation of SARS-CoV-2 infection was obtained from nasopharyn-
geal swabs and PCR analysis A proportion of patients that exhibited
clinical and laboratory findings compatible with COVID-19 but failed to
test positive, also received treatment and were included in the study.
The primary endpoint was to evaluate the clinical outcome (need for
mechanical ventilation or death) of the cohort. Two study periods were
defined: from March 3 to March 31, 2020 (beginning of epidemic until
peak of incidence) and from April 1 to May 7, 2020 (second half of
epidemic). The cutoff was established on April 1st based on the peak
incidence and the shift in the treatment protocol. The majority of patients
received ventilatory support, combinations of antimicrobials, anticoag-
ulants, corticoids and interleukin inhibitors. Antivirals were preferen-
tially given in the first period. The study was designed and conducted by
a multidisciplinary in-hospital group (including physicians belonging to
critical care, infectious diseases, internal medicine, pneumology, hema-
tology units and other specialists) specifically created for the COVID-19
epidemic.
2.2. Data and statistical analysis
Quantitative variables are shown as mean (SD) or median (IQR), and
qualitative variables as proportions. Fisher’s t-test or Mann-Whitney’s U
test was used to compare the groups based on the distribution of quan-
titative variables. Pearson’s chi-square (χ2) test or Fisher’s exact test was
used for the proportion comparison. The primary outcome was defined as
a compound of all-cause mortality and the need for invasive mechanical
ventilation. Patients received invasive mechanical ventilation according
to PaO2/FiO2 ratio and clinical parameters like tachypnea, altered res-
piratory function (tachypnea >30 with increased respiratory effort
despite oxygen supplement or non-invasive mechanical ventilation
(NIMV), and use of ancillary musculature) and/or hemodynamic insta-
bility, with or without impairment in the level of consciousness.
A single-time logistic regression test was performed, setting the
combined event death or mechanical ventilation as a dependent variable;
subsequently, a multiple logistic regression was performed including all
variables showing statistical significance (or a tendency to statistical
significance with a value of p < 0.2) in the univariate analysis. Addi-
tionally, a survival analysis was performed using the Cox univariate and
multivariate regression method and Kaplan-Meier curves, by comparing
the time to the need for invasive mechanical ventilation or death in both
groups. The results are expressed as hazard ratio (HR) with 95% confi-
dence interval. Comparing tocilizumab, the endpoint was only mortality.
The statistical analysis was carried out with the statistical package Stata/
IC 16.1 (College Station, TX 77845) and user-written commands. p-value
was considered as statistically significant at <0.05.
Table 1
Main clinical characteristics of the COVID-19 cohort.
N (participants) 685
Age (years) 68,89 (16,12)
Sex (male) 58,39%
History of hypertension 46,71%
Pulmonary disease history 77,81% no pulmonary disease
9,49% COPD
2,48% emphysema
10,22% other respiratory disease
Smoker 13,93%
PaO2/FiO2 at admission 262,22 (90,22) mm Hg
range 47–470
>300 mm Hg 36,48%
200–300 mm Hg 41,98%
100–200 mm Hg 16,51%
<100 mm Hg 5,03%
PCR SARS-CoV-2 87,01% positive
2,04% negative
10,94% negative, but received treatment
Pulmonary CT performed 16,35%
Pulmonary affectation Unilateral 26,41%
Bilateral 73,59%




Minimum Lymphocyte count (/μL) 791 (539)




Minimum platellet count (x1000/μL) 194 (102)
Maximum GPT (UI/L) 51 (IQR 72)




Maximum Troponin (ng/L) 17 (IQR 31)





Median hospital stay 11 (2–72)
ICU admission 103 (15.0%)
ICU intubation 83 (12.1%)
ICU stay 14 (8–31)
Fig. 1. Evolution of hospital and ICU admission during the pandemic, distinguishing b
in the first (left)and second (right)periods, respectively.
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2.3. Treatment protocol
At the beginning of the COVID-19 epidemic (March 2nd, 2020), the
standard of care in our institution for patients presenting with hypoxemia
included respiratory support, lopinavir/ritonavir (LPV/r), azithromycin,
hydroxychloroquine, enoxaparin, interferon 1-β and methylpredniso-
lone. Methylprednisolone dosage varied up to the physician in charge:
internists preferentially prescribed a 3-day 250 mg bolus scheme fol-
lowed by tapering dose, while pneumologists tended to prescribe meth-
ylprednisolone at 1 mg/kg of body weight. Ceftriaxone was also
prescribed upon physician discretion. By the end of March 2020, LPV/r
was abandoned due to the lack of efficacy reported [33] and the presence
of troublesome pharmacokinetic interactions, especially among critically
ill patients. At that time, IL-6 inhibitor tocilizumab was added to the
protocol aimed at patients meeting ARDS criteria [34] and biochemical
alterations suggestive of severe systemic inflammation (ferritin levels
>1000 ng/ml and/or IL-6 values > 50 pg/ml). IL-1 inhibitor anakinra
was also used in patients meeting ARDS criteria and biochemical alter-
ations suggesting severe systemic inflammation but with IL-6 levels less
than 50 pg/ml and/or 4-fold blood ALT levels over the normal upper
limit.
Etoposide was offered to patients that, despite having received bo-
luses of 250 mg of methylprednisolone for three days plus tocilizumab or
anakinra, kept on deteriorating their PaO2/FiO2 ratios and PCO2 values
[35]. Orotracheal intubation, mechanical ventilation and prone posi-
tioning were applied when necessary according to the course of respi-
ratory function. Given that, since the beginning of the study period, there
was evidence that severe COVID-19 infection predisposed to thrombosis,
the great majority of patients received prophylactic enoxaparin (40 mg
per day for 14 days). Therapeutic anticoagulation was initiated when
thrombotic complications appeared and/or at the physician’s discretion
in patients with high risk of thrombosis according to the clinical and
laboratory findings.
3. Results
Within the study period (March 3rd to May 7th, 2020) a total of 1205
patients tested positive for PCR SARS-CoV-2 in our center. After
excluding mild and asymptomatic patients and those under 18 years, 685
COVID-19 patients were included in the study (58.4% males, mean age.oth periods. The list of treatments represents the medications and theraoies used
B.-M. Luis et al. Journal of Translational Autoimmunity 4 (2021) 10008668.9  16.1 years). The main clinical characteristics of the cohort are
detailed in Table 1. More than 45% of the cohort had a history of hy-
pertension, and 63.5% of patients presented with a PaO2/FiO2 ratio<300.
Nearly half of patients showed maximum ferritin levels>1000 ng/ml and
IL-6 levels >50 pg/ml. Average D-dimer level was 1.4 μg/mL. For com-
parison, we subdivided patients in two groups: those admitted before
(first period, n ¼ 408) and after (second period, n ¼ 277) the peak of the
local epidemic.
Although our treatment protocol varied throughout the study period,
according to emerging evidence and international recommendations, the
entire cohort was treated with a relatively homogeneous protocol in both
periods, with the exception of lopinavir/ritonavir and interferon, which
were abandoned in the second period. Fig. 1 depicts the epidemic curveTable 2
Clinical and demographic variables in the two periods.






Age >70 years 80.03 (7.13)
Female 157 (38.48%)
Duration of symptoms prior to admission (days) 7.01 (4.99)
Hypertension 43.87%
No prior pulmonary disease 311 (76.23%)
COPD 37 (9.07%)
Emphysema 11 (2.70%)




PCR negative 5 (1.23%)
PCR positive 367 (89.95%)
PCR negative but received treatment 36 (8.82%)
Chest CT performed 56 (13.73%)
Bilateral pneumoniae 77%





Lymphocyte count (minimum) 711 (23)






























in our center, and the treatment scheme preferentially used in the two
periods.
The similarities and differences of the two periods are shown in
Table 2. Patients in the first period were slightly younger (66.5 vs 71.1
years, p¼ 0.003) and presented with higher ferritin levels (1520 vs 1221
ng/ml, p ¼ 0.017), more profound lymphopenia (711 vs 909, p <
0.0001), and higher IL-6 levels (679 vs 194 pg/ml, p < 0.0001). How-
ever, PaO2/FiO2 ratio at presentation (256 vs 270 mm Hg, p ¼ 0.0563)
and D-dimer levels (3.59 vs 3.39 μg/mL, p ¼ 0.65) were similar. Non-
invasive ventilation was preferentially used in the first period (16.7%
vs 6.49%, p ¼ 0.0002). Noticeably, treatment modalities were equally
distributed in the two periods except for lopinavir/ritonavir and inter-
feron that were used almost exclusively in the first period (23.8% andSecond period (N ¼ 277) Difference P




84.45 (7.03) 4.43 (5.95 to 2.90) <0.0001
128 (46.20%) 7.73 (0.2–15%) 0.0441






33 (12%) 3.23% (2.08 to 8.5) 0.23
270.41 (84.72) 13.88 (28.12 to 0.37) 0.0563
















68 (5.45) 54 0.0246































16.18% 6.49% 9.68% 0.0002
Days under non-
invasive support
4.15 6.28 2.12 0.0152
Mechanical ventilation 16.91% 4.69% 12.22% <0.0001
















Overall thrombotic complication rate
Pulmonary embolism 3.19% 3.61% 0.946
Arterial embolism 0.98% 0.72%
Venous embolism 0.74% 0.36%
ARDS 73.95% 68.59% 0.1264
ICU admission 20.09% 6.13% <0.0001
Death 15.44% 17.68% 0.4356
Table 4
Clinical characteristics and outcomes of patients treated and not treated with








Age 78.5 (62.5–87.5) 64.5 (57.5–72.5) <0.0001
<50 years 8.06% 13.61% <0.0001
50–70 years 29.38% 55.10%
>70 years 62.56% 31.29%
Female 35.5% 20.40% 0.002
Duration of symptoms
prior to admission (days)
7.35 7.90 <0.0001
Overall stay (days) 10 (range, 7–17) 17 (range, 10–27) <0.0001
ICU stay (days) 20 (range, 10–50) 13.5 (range,
10–30)
0.944
History of hypertension 54.03% 48.97% 0.343
Prior pulmonary disease




Smoker 13.80% 17.01% 0,4081
PaO2/FiO2 at admission
(mm Hg)
255.14 (84,05) 208.06 (86,78) <0.0001




pCO2 (mm Hg) 35.38 (8.73) 33.36 (7.29) 0.0263











600 (400–900) 500 (400–700) 0.007











GPT (UI/L) 54 (30–98) 113 (64–188) <0.0001
LDH (UI/L) 380 (302–483) 421 (338–577) 0.046
<250 10.19% 4.83% 0.003
250–500 67.69% 57.93%
>500 21.84% 37.24%
Troponin (ng/L) 33.5 (14–79) 15.5 (8–29,5) <0.0001
D-Dimer (μg/mL) 1.6 (0.9–3.8) 2.4 (1–7.8) 0.027










Days under IMV 20 (10–36) 12 (8–27) 0.515
Ceftriaxone 83.41% 93.19% 0.006
Azithromycin 96.21% 100% 0.023
Hydroxychloroquine 85.31% 98.64% <0.0001
Lopinavir/ritonavir 12.80% 12.93% 0.547
Interferon 1-beta 22.27% 31.29% 0.06
Methylprednisolone











(continued on next page)
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either in bolus or mg/kg dosage, were widely prescribed in both periods
(360 patients, 88.1% vs 243 patients, 87.4%, p ¼ 0.026). Tocilizumab
was administered in 107 patients, 26.3% and 56 patients, 20.2%,
respectively. Anakinra (n ¼ 9) and etoposide (n ¼ 14) were selectively
offered to more severe cases, resistant to tocilizumab. Etoposide was used
in severely ill patients not responding to interleukin inhibitors that
showed laboratory findings similar to that of secondary HLH. The great
majority of patients received anticoagulation therapy in both periods
(92.7% vs 95.4%, p ¼ 0.322).
Table 3 shows the clinical outcome of patients in both periods.
Interestingly, patients in the second period needed less mechanical
ventilation (4.69% vs 16.91%, p < 0.0001), and ICU admission (6.1% vs
20.1%, p < 0.0001). Yet, mortality rate was similar in both periods
(15.4% vs 17.7%, p¼ 0.435), as well as overall infectious and thrombotic
complication rates.
A total of 163 patients were treated with tocilizumab plus methyl-
prednisolone. As shown in Table 4, 66 (40.5%) were admitted to the ICU,
54 required mechanical ventilation (33.13%),and 13 patients died
(7.98%).
Overall, there were 83 episodes of infectious complication in 39 pa-
tients, 90% of which occurred at the ICU. The survival analysis showed
that the hazard risk of death or need for mechanical ventilation was
slightly increased in the first period, yet without statistical significance
(Fig. 2).
After multiple regression analysis, our model has an AUC ¼ 0.9274.
Tocilizumab showed a tendency to be protective for the combined
endpoint, with an OR 0.35 without statistical significance (CI95%
0.10–1.20, p¼ 0.11), but when only mortality was analyzed, tocilizumab
shows an OR 0.21 (0.0566–0.7535, p ¼ 0.017). Even in Cox multiple
regression showed HR 0.35 (CI95% 0.14–0.90, p ¼ 0.03).
4. Discussion
Since the early reports from China, it was clear that throughout the
SARS-CoV-2 pandemic, ICU admission and mechanical ventilation re-
quirements were key issues to acknowledge and deal with [3,4]. Subse-
quent worldwide expansion of the virus led to overwhelming of ICUs in
many countries and the need for ICU beds and ventilators dramatically5








No 95.26% 91.16% 0.278
Pulmonary embolism 3.32% 6.12%
Arterial complications 0.95% 0.68%
Venous complications 0.47% 2.04%
ARDS 76.78% 93.20% <0.0001
ICU requirement 12.80% 40.5% <0.0001
Mortality rate 24.17% 7.98% <0.0001
B.-M. Luis et al. Journal of Translational Autoimmunity 4 (2021) 100086increased in a short period of time [1,2,5,6,36,37]. In our center, some
operating rooms and post-surgery recovery units had to be rapidly
transformed into new ICU facilities by mid-March 2020, when up to 56
ICU beds and ventilators were required. At that point, SARS-CoV-2 pos-
itive patients occupied 80% of the remaining hospital beds.
At the beginning of the epidemic, sound evidence on the effectiveness
of the various treatment options lacked. However, pathophysiologic
research studies suggested that immune dysregulation was a key feature
in the clinical course of moderate and severely ill COVID-19 patients
[8–11]. Therefore, we hypothesized that targeting immune dysregulation
would result in fewer need for ventilator and lower mortality.Fig. 2. Survival analysis and kaplan-Meier curves by perio
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4.1. Hyperinflammatory response in severely ill COVID-19 patients
There is growing evidence showing that COVID-19 infection is a
biphasic disease [11]. The initial stage, at which pre-symptomatic or
pauci-symptomatic patients exhibit a preliminary and reversible state of
immune-suppression associated to the viral load, ideally benefits from
antivirals. To date, no specific antiviral drugs, including LPV/r and
remdesivir, have proven effective for the treatment of patients with se-
vere COVID-19 in terms of reduction of mortality or requirement of
mechanical ventilation [33,38]. The combination of LPV/r, interferon
β-1b and ribavirin was safe and superior to lopinavir–ritonavir alone in
alleviating symptoms and shortening the duration of viral shedding and
hospital stay, only in patients with mild to moderate COVID-19 infection,
yet not in severe cases [39].
Ideally, effective antivirals capable of inhibiting SARS-CoV-2 repli-
cation should be effective at the first stage of the disease, and likely
thereafter, when the dysregulated immune response predisposes to se-
vere multiorgan damage [9–11]. Unfortunately, as of August 30th, 2020,
we lack highly efficient antivirals against SARS-CoV-2 [33,38,39]. In our
experience, there was no difference in mortality between the two periods
of the first wave, in which the only difference in terms of drug treatment
was the use of lopinavir/ritonavir plus interferon 1β. Etoposide was used
in severely ill patients not responding to interleukin inhibitors that
showed laboratory findings similar to that of secondary HLH. In fact,d. Endpoint: death or need for mechanical ventilation.
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line with previous studies reporting unclear in vivo efficacy in severely ill
COVID-19 patients [33].
Hydroxychloroquine was the first drug specifically directed to the
virus according to the study by Raoult et al. [40]. However, subsequent
reports and clinical trials failed to demonstrate a clear benefit, leading to
its withdrawal from many ongoing clinical trials [7,41,42]. As we used
hydroxychloroquine equally in both periods, no statements can be made
regarding its impact in our cohort.4.2. Corticosteroids and tocilizumab as the cornerstone of aggressive
immune downregulation in severely ill COVID-19 patients
Corticosteroid use in COVID-19 patients has been a controversial
issue since the beginning of the pandemic. Initially, the World Health
Organization (WHO) recommended against the routine use of cortico-
steroids for treatment of viral pneumonia outside clinical trials [2,19].
Contrarily, the Corticosteroid Guideline Task Force of the Society of Critical
Care Medicine (SCCM) and the European Society of Intensive Care Medicine
(ESICM) issued guidelines supporting the use of glucocorticoids in crit-
ically ill patients including those with ARDS [20]. They found moderate
quality/certainty of evidence for a reduction in the duration of me-
chanical ventilation and improved overall survival [43]. Thus, a rationale
for the prolonged use of corticosteroids in COVID-19 related ARDS was
initially proposed [23]. Further evidence supported the use of gluco-
corticoids in moderate and severely ill COVID-19 patients [7,17,18,25],
suggesting that dexamethasone or methylprednisolone would reduce
mortality in the more severe cases. The recent publication by Fadel et al.
[5], showed that an early short course of methylprednisolone in patients
with moderate to severe COVID-19 infection reduced the escalation ofFig. 3. Tocilizumab survival analysis
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care and reduced mortality compared to late corticoid administration
(34.9% vs. 54.3%, p ¼ 0.005). A significant reduction in median hospital
stay was also observed in the early corticosteroid group (8 vs. 5 days, p <
0.001). More recently, the preliminary data from the RECOVERY trial
demonstrated a statistically significant reduction of mortality at 28 days
(21.6% vs 24.6%, p < 0.001) in patients allocated to dexamethasone (6
mg per day) versus those treated with standard of care [7]. In fact, at
present, dexamethasone is the only drug showing evidence for a reduc-
tion in mortality compared with the standard of care according to ran-
domized clinical trials.
Upon previous research [8,9,11], we realized that immune dysregu-
lation and systemic inflammation played a relevant role in promoting
multi-organ damage of severe COVID-19. Therefore, we prescribed glu-
cocorticoids on a regular basis to patients with respiratory failure (PaO2
<60 mmHg) and/or bilateral lung infiltrates, rapid imaging progression,
and severe inflammatory response. We did not find differences in
outcome regarding dosage and both types (bolus and maintenance)
resulted beneficial. Further studies are needed to elucidate this point and
the impact of other potential confounders. Although we cannot compare
the impact of glucocorticoids between the two periods, the mortality rate
in our cohort is lower than that of comparable series from other in-
stitutions [36,37], supporting the idea that early aggressive glucocorti-
coid therapy is feasible and effective. In fact, the mortality rate in our
cohort (16,35%) is significantly lower than that reported by the con-
ductors of the RECOVERY Trial (22,9%) [7].
Off-label use of tocilizumab was proposed since the beginning of the
pandemic upon reports from China and Italy, which suggested a benefit
among patients exhibiting severe systemic inflammation (with elevated
levels of plasma ferritin and IL-6) and respiratory failure [26,27]. These
preliminary reports were further supported by new evidence from caseand Kaplan-Meier curves (death).
B.-M. Luis et al. Journal of Translational Autoimmunity 4 (2021) 100086reports and observational studies [28,29]. In fact, 64 randomized trials
on the efficacy of various tocilizumab schemes are currently ongoing
(www.clinicaltrials.gov).
To our knowledge, our series is the largest cohort of patients treated
with tocilizumab plus methylprednisolone (n ¼ 163). A similar prior
experience from Brescia in Italy resulted in an overall mortality rate of
20% over 100 patients treated with tocilizumab plus dexamethasone.
However, the optimal dosing schedule remains unclear [27]. At the
beginning of April 2020, and due to national shortage, we were forced to
treat patients with only one-two doses of 8 mg/kg, instead of the usual
three doses. At our institution, candidates for tocilizumab therapy were
selected among severe ill COVID-19 patients upon clinical and laboratory
findings. Availability of medication and the presumed potential of benefit
for each individual conditioned the indication of treatment, thus not all
patients with a priori indication for tocilizumab received treatment
(Table 4). Interestingly, although patients receiving tocilizumab showed
significant lower PaO2/FiO2 ratio at admission, higher IL-6 and ferritin
levels, and required more NIMV and ICU admission, mortality rate was
significantly lower compared to those with theoretical indication who
remained untreated (7.89% vs 24.17%, p < 0.0001, see Fig. 3). Patients
treated with tocilizumab who kept on worsening their respiratory con-
dition and systemic inflammation biochemical parameters, were subse-
quently treated with anakinra [44] or etoposide [35].
Secondary infections occurred unfrequently among patients hospi-
talized. Yet, 90% of infections were recorded at the ICU (primarily me-
chanical ventilation associated pneumonia, catheter related bacteremia,
and urinary tract infections). It seems likely that the widespread use of
third generation cephalosporins may have decreased the occurrence of
nosocomial infection. Additionally, infection rates may have been
influenced by the general overwhelming situation of the center, the poor
availability of individual protective equipment at somemoments, and the
need for prone positioning of many patients.
4.3. When should patients with severe COVID-19 be intubated?
The pathophysiological mechanism behind acute respiratory distress
syndrome (ARDS) is a pulmonary inflammatory process that induces non-
hydrostatic protein-rich pulmonary edema, leading to profound hypox-
emia, decreased lung compliance, and increased intrapulmonary shunt
and dead space, with subsequent increase in ventilation/perfusion
mismatch. ARDS criteria, as well as its severity classifications were used
[34]. According to these criteria, ARDS is a common finding among se-
vere COVID-19 pneumonia patients. In our experience, over 58% of
COVID-19 patients developed ARDS.
According to international guidelines [45], adult patients presenting
with ARDS (PaO2/FiO2 <300) are immediate candidates for orotracheal
intubation and mechanical ventilation. However, unlike usual ARDS,
SARS-CoV-2 related ARDS may present with alarming PaO2/FiO2 ratios
(commonly under 150) but relatively preserved ventilatory function
(mild dyspnea with or without tachypnea). Additionally, patients
commonly show preserved oxygen extraction and adequate organ
perfusion without lactic acidosis. Although upon ARDS Berlin criteria, all
such patients would be candidates for immediate intubation, this
particular ARDS profile allowed avoidance of invasive mechanical
ventilation in a significant proportion of our cohort. We hypothesize that
SARS-CoV-2 related ARDS distinct pathophysiologic features permit
management of many critically ill COVID-19 patients with non-invasive
ventilatory support, waiting for the reversal effect of anti-inflammatory
therapy.
We observed that severe COVID-19 ARDS patients benefited from
adequate oxygenation and correction of ventilation/perfusion mismatch,
with alveolar recruitment helped by prone positioning and mild PEEP,
which on the one hand, decreases the intrapulmonary shunt, improving
arterial oxygenation, and on the other hand, decreases the amount of
lung tissue exposed to alveolar opening-closing, thus reducing the risk of
ventilator-induced lung injury. Prone positioning is commonly used in8
patients under mechanical ventilation who persist with severe respira-
tory impairment despite sedation-analgesia, muscle relaxation and
recruitment measures, although it is also described and can be used in
patients under non-invasive mechanical ventilation as in COVID-19 [46,
47].
When comparing the need for mechanical ventilation between the
both periods, as we gained experience, we readily learned that many
COVID-19 ARDS patients tolerated alarmingly low PaO2/FiO2 ratios
(even under 100) without the need for intubation and mechanical
ventilation, therefore avoiding invasive measures and ICU stay, yet
without a negative impact on mortality.
This is, to our knowledge, the biggest report of patients treated with
tocilizumab and glucocorticoids. However, this study has some limita-
tions. It is a single center retrospective case review without a formally
defined control group in terms of treatment protocol. This is partly
attributable to the lack of standardized treatment guidelines, especially
at the beginning of the epidemic. However, our treatment protocol was
maintained rather homogeneously throughout the study period in a large
sample of hospitalized patients. Our overall mortality rate also compared
favorably with previous series. Acknowledging potential sources of bias,
we found a significantly reduced mortality rate among patients treated
with tocilizumab plus corticoids compared to theoretical candidates who
did not received such treatment. In line with previous reports, aban-
donment of lopinavir/ritonavir plus interferon 1β combination showed
no impact on mortality. Finally, infectious complications rate was
acceptable and the majority of them occurred in the ICU where predis-
posing factors may have also contributed.
In summary, we report favorable outcomes from a large single center
cohort of hospitalized COVID-19 patients with respiratory impairment,
treated with early glucocorticoid therapy and interleukin inhibitors. The
combination of methylprednisolone and tocilizumab resulted in
improved mortality and acceptable complication rates among severely ill
COVID-19 patients. Upcoming results from clinical trials will eventually
elucidate the effectiveness of immunomodulatory therapy in this clinical
setting.
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